Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder

April 16, 2023 · Benzinga

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology.

The open-label Phase 2 study tested psilocybin paired with psychological support in 30 patients with curable and incurable cancer. Participants were divided into cohorts of 3 to 4 and each was given a 25 mg single dose of COMPASS 

CMPS-0.10%+ Free Alerts’ synthetic psilocybin COMP360.

Dosing was done simultaneously on all patients, who were located in adjacent rooms open to a common space, in a one-on-one therapist/patient ratio. Group therapy was provided throughout one preparation and two integration sessions, which were supplemented by individual therapy.

Data from the study showed a sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms, as measured on MADRS scores, from baseline to 8 weeks post-treatment. 

Self-reported measures of depressive symptoms supported the findings, with an average 48% reduction from baseline and a 53% decrease in depression severity.

Sunstone’s CEO and the study’s PI, Dr. Manish Agrawal said the trial is “the first of its kind,” conducted within a community hospital cancer center in groups and using a lower therapist-to-patient ratio than previous psilocybin therapy studies. 

“This approach has been shown to be effective in delivering a significant improvement in these patients’ depression symptoms and, if replicated in larger studies, could open the door to a wider and faster adoption of psilocybin therapy in the future,” Dr. Agrawal said.

Chief therapist Bill Richards, Ph.D. commented that although the number of study participants was small, the results from the open-label study add to the growing body of evidence on psilocybin therapy for mental distress and provides hope to cancer patients and their families of an effective treatment for depression associated with their condition which, he says, “impacts 1 in 4 people with cancer and often becomes a debilitating aspect of their diagnosis.” (Full Story)

In categories:Psychedelics Research
Next Post

April 19 Bicycle Day Celebrates The First LSD Trip

While most people in the cannabis industry are gearing up for the high holiday of April, 20 or 420, our good friends in the psychedelic industry have their own day of celebration. It’s called Bicycle Day and it falls on…
Previous Post

Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations

Clinical-stage biopharma company atai Life Sciences  ATAI-6.00%+ Free Alerts announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of proprietary R-ketamine, PCN-101. Open-label, the trial is set to assess safety, tolerability and pharmacokinetic profile of 60mg,…
Random Post

New Hampshire House Approves Adult-Use Cannabis Legalization Bill

The New Hampshire House on Thursday passed an adult-use legalization bill by a 272-109 vote, The Center Square reports. The measure moves next to the state Senate.  New Hampshire is the lone New England state to not allow cannabis sales to adults.   In a…
Random Post

Top Intelligence Official Says Past Marijuana Use Is Not Disqualifying For Security Clearance In Interest Of Recruiting ‘Talent’

A top U.S. intelligence official reaffirmed on Wednesday that it is not the federal government’s current policy to deny people security clearances based on past marijuana use alone, stating that it is counterproductive to recruitment efforts, especially amid the growing…
Random Post

Marijuana microbusinesses: What are they and how do they work?

Missourians voted to legalize recreational, adult-use marijuana in November. That constitutional amendment also established a framework for marijuana "microbusinesses" — business licenses intended to allow more "everyday folks" to participate in the state's growing marijuana industry. "Right now, the way…
Random Post

UK Prime Minister’s Office: ‘No Plans’ to Reclassify Cannabis from Class B to Class A Drug

The United Kingdom prime minister’s office is distancing itself from a proposal from Conservatives that would reclassify cannabis from a Class B to Class A drug in the country, with a Downing Street spokesperson telling The Guardian that there are “no plans” to…